The latest price target for Standard BioTools (NASDAQ:LAB) was reported by TD Cowen on November 5, 2025. The analyst firm set a price target for $1.35 expecting LAB to rise to within 12 months (a possible 41.41% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Standard BioTools (NASDAQ:LAB) was provided by TD Cowen, and Standard BioTools maintained their hold rating.

There is no last upgrade for Standard BioTools

The last downgrade for Standard BioTools Inc happened on February 27, 2025 when Keybanc changed their price target from N/A to N/A for Standard BioTools Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Standard BioTools, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Standard BioTools was filed on November 5, 2025 so you should expect the next rating to be made available sometime around November 5, 2026.

While ratings are subjective and will change, the latest Standard BioTools (LAB) rating was a maintained with a price target of $1.55 to $1.35. The current price Standard BioTools (LAB) is trading at is $0.95, which is out of the analyst’s predicted range.